Drug intelligence / Profile preview

NPT520-337

Development stage: Preclinical
Lead developer: Neuropore Therapies
Modality: Small Molecules
Administration: Oral

Overview

NPT520-337 is a small molecule inhibitor of the phosphatidylinositol 3-kinase (PI3K) family, designed to cross the blood-brain barrier. It is being developed as a potential therapy for glioblastoma and other neoplasms. The drug acts by inhibiting PI3Ks, which are key regulators of cell growth and survival pathways often dysregulated in cancer. Preclinical studies suggest that NPT520-337 may sensitize glioblastoma multiforme (GBM) to immune checkpoint inhibitors and/or radiation therapies by modulating immune responses within the tumor microenvironment[1][6]. The compound is currently in preclinical development.

Targets

PI3K (Phosphoinositide-3-kinase regulatory subunit 6)

Beyond the preview

Go deeper on NPT520-337.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NPT520-337.

Explore the full profile